Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib plus bevacizumab versus osimertinib alone in T790M-positive EGFR-mutant advanced NSCLC
NL-OMON47703Phase 2Active, not recruiting
- Sponsor
- European Thoracic Oncology Platform
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of osimertinib and bevacizumab in non-small cell lung cancer (NSCLC) and EGFR-mutated non-small cell lung cancer (2 arms), sponsored by European Thoracic Oncology Platform. Primary endpoint: Progression-free survival. Started Jul 2018; status: active, not recruiting.
02
Drugs
osimertinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on NL-OMON47703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47703.